MHRA Registration Approval for BioPerfectus Monkeypox Virus Real Time PCR Kit

Company news
2022-08-11

SHANGHAI, CHINA, August 11, 2022—Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “BioPerfectus”) is pleased to announce that Monkeypox Virus Real Time PCR Kit has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and is now officially available for Great Britain and Northern Ireland market.

 

There were 2,859 confirmed cases and highly probable cases of monkeypox as of Aug. 4. in the UK. Earlier last month, the monkeypox outbreak set its highest alert, “a public health emergency of international concern” was declared by the World Health Organization.

 

Based on real-time PCR technology, BioPerfectus Monkeypox Virus Real Time PCR Kit is specifically designed for the F3L gene areas of the monkeypox virus. In addition, the kit also contains a housekeeping gene (RNase P) as an internal control (IC) for specimen sampling and nucleic acid extraction.

 

BioPerfectus Monkeypox Virus Real Time PCR Kit has been validated, approved, and used to test and track the Monkeypox virus in several high and key-level public and private laboratories worldwide. So far, over 100,000 test kits have been delivered to over 100 countries around the globe.

 

 


About Bioperfectus

 

Bioperfectus, a publicly listed company on the Shanghai Stock Exchange (SSE:688399), has been a leading molecular diagnostic solution provider specializing in infectious diseases since 2010. With headquarters in Jiangsu, and subsidiaries in Shanghai, Beijing, Xi'an, Taizhou, Hainan, and Yinchuan, Bioperfectus is a pioneer in the molecular diagnostics market with products ranging from real-time PCR kits, nucleic acid extraction systems, rapid tests, and automated laboratory devices. Young and passionate, Bioperfectus is working steadily and firmly to achieve the dream of creating a healthier future for our next generations. For more information, please follow us on LinkedIn or visit www.bioperfectus.com.

 

 

Media Contact: marketing_global@bioperfectus.com

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14